Clinical Trials – Page 5

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

2 months ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

2 months ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

2 months ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher

2 months ago talkbio0Tagged Clinical Trials, Colorectal Carcinoma, Exelixis, regorafenib, STELLAR-303, surge, Tecentriq, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

2 months ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

2 months ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

Zealand Pharma’s Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks

2 months ago talkbio0Tagged Clinical Trials, Dapiglutide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Obesity, Safety, Weight Loss, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1; GLP-2; weight loss; obesity; phase 1b trial; clinical trial; dual agonist; safety

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

2 months ago talkbio0Tagged ABS-0871, ABS-1230, Actio, Biosciences, Charcot-Marie-Tooth Disease, Clinical Trials, Drugs, Orphan, Epilepsy, Infrequent, Inhibitor, KCNT1 gene, Regeneron, Series B financing, TRPV4 protein, human

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

2 months ago talkbio0Tagged BioNTech, BNT211, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Clinical Trials, Gaithersburg, layoffs, Manufacturing Facilities, Maryland (geographic location)

BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial